{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:21:37Z","timestamp":1793506897240,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T00:00:00Z","timestamp":1499817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T00:00:00Z","timestamp":1499817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer epithelium, making it a promising target for molecular imaging and therapy. Recently, several studies found unexpected PSMA radiotracer uptake by thyroid tumors, including radioiodine-refractory (RAIR) cancers. PSMA expression was reported in tumor-associated endothelium of various malignancies, however it has not been systematically addressed in thyroid tumors. We found that PSMA was frequently expressed in microvessels of thyroid tumors (120\/267), but not in benign thyroid tissue. PSMA expression in neovasculature was highly irregular ranging from 19% in benign tumors to over 50% in thyroid cancer. Such heterogeneity was not directly attributed to endothelial cell proliferation as confirmed by immunostaining with proliferation-associated endothelial marker CD105. PSMA expression was associated with tumor size (p\u2009=\u20090.02) and vascular invasion in follicular carcinoma (p\u2009=\u20090.03), but not with other baseline histological, and clinical parameters. Significant translational implication is that RAIR tumors and high-grade cancers maintain high level of PSMA expression, and can be targeted by PSMA ligand radiopharmaceuticals. Our study predicts several pitfalls potentially associated with PSMA imaging of the thyroid, such as low expression in oncocytic tumors, absence of organ specificity, and PSMA-positivity in dendritic cells of chronic thyroiditis, which is described for the first time.<\/jats:p>","DOI":"10.1038\/s41598-017-05481-z","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T05:54:25Z","timestamp":1499320465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["PSMA expression by microvasculature of thyroid tumors \u2013 Potential implications for PSMA theranostics"],"prefix":"10.1038","volume":"7","author":[{"given":"Andrey","family":"Bychkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanee","family":"Vutrapongwatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6092-0488","authenticated-orcid":false,"given":"Supatporn","family":"Tepmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somboon","family":"Keelawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,12]]},"reference":[{"key":"5481_CR1","first-page":"927","volume":"7","author":"JS Horoszewicz","year":"1987","unstructured":"Horoszewicz, J. S., Kawinski, E. & Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res \n                           7, 927\u2013935 (1987).","journal-title":"Anticancer Res"},{"key":"5481_CR2","first-page":"227","volume":"53","author":"RS Israeli","year":"1993","unstructured":"Israeli, R. S., Powell, C. T., Fair, W. R. & Heston, W. D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res \n                           53, 227\u2013230 (1993).","journal-title":"Cancer Res"},{"key":"5481_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","volume":"30","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita, Y. et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg \n                           30, 628\u2013636 (2006).","journal-title":"World J Surg"},{"key":"5481_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","volume":"50","author":"P Mhawech-Fauceglia","year":"2007","unstructured":"Mhawech-Fauceglia, P. et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology \n                           50, 472\u2013483 (2007).","journal-title":"Histopathology"},{"key":"5481_CR5","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res \n                           3, 81\u201385 (1997).","journal-title":"Clin Cancer Res"},{"key":"5481_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/modpathol.2012.66","volume":"25","author":"MC Haffner","year":"2012","unstructured":"Haffner, M. C. et al. High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol \n                           25, 1079\u20131085 (2012).","journal-title":"Mod Pathol"},{"key":"5481_CR7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.humpath.2009.06.003","volume":"40","author":"MC Haffner","year":"2009","unstructured":"Haffner, M. C. et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol \n                           40, 1754\u20131761 (2009).","journal-title":"Hum Pathol"},{"key":"5481_CR8","doi-asserted-by":"publisher","first-page":"e0125924","DOI":"10.1371\/journal.pone.0125924","volume":"10","author":"HL Wang","year":"2015","unstructured":"Wang, H. L. et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One \n                           10, e0125924, doi:10.1371\/journal.pone.0125924 (2015).","journal-title":"PLoS One"},{"key":"5481_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/apm.12195","volume":"122","author":"AG Wernicke","year":"2014","unstructured":"Wernicke, A. G. et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS \n                           122, 482\u2013489 (2014).","journal-title":"APMIS"},{"key":"5481_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000297","author":"AG Wernicke","year":"2016","unstructured":"Wernicke, A. G., Kim, S., Liu, H., Bander, N. H. & Pirog, E. C. Prostate-specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: implications for PSMA-targeted therapy. Appl Immunohistochem Mol Morphol. doi:10.1097\/PAI.0000000000000297 (2016).","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"5481_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","volume":"70","author":"A Baccala","year":"2007","unstructured":"Baccala, A., Sercia, L., Li, J., Heston, W. & Zhou, M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology \n                           70, 385\u2013390 (2007).","journal-title":"Urology"},{"key":"5481_CR12","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/modpathol.2011.112","volume":"24","author":"MK Samplaski","year":"2011","unstructured":"Samplaski, M. K., Heston, W., Elson, P., Magi-Galluzzi, C. & Hansel, D. E. Folate hydrolase (prostate-specific membrane antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol \n                           24, 1521\u20131529 (2011).","journal-title":"Mod Pathol"},{"key":"5481_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2867-14-26","volume":"14","author":"N Nomura","year":"2014","unstructured":"Nomura, N. et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int \n                           14, 26 (2014).","journal-title":"Cancer Cell Int"},{"key":"5481_CR14","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","volume":"135","author":"AG Wernicke","year":"2011","unstructured":"Wernicke, A. G. et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med \n                           135, 1486\u20131489 (2011).","journal-title":"Arch Pathol Lab Med"},{"key":"5481_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol \n                           13, 226\u2013235 (2016).","journal-title":"Nat Rev Urol"},{"key":"5481_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh, A. et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging \n                           40, 486\u2013495 (2013).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5481_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CCO.0000000000000338","volume":"29","author":"M Luster","year":"2017","unstructured":"Luster, M., Pfestroff, A. & Verburg, F. A. Recent advances in nuclear medicine in endocrine oncology. Curr Opin Oncol \n                           29, 1\u20136 (2017).","journal-title":"Curr Opin Oncol"},{"key":"5481_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00259-015-3212-5","volume":"43","author":"FM Mottaghy","year":"2016","unstructured":"Mottaghy, F. M., Behrendt, F. F. & Verburg, F. A. 68Ga-PSMA-HBED-CC PET\/CT: where molecular imaging has an edge over morphological imaging. Eur J Nucl Med Mol Imaging \n                           43, 394\u2013396 (2016).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5481_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/pros.2990180305","volume":"18","author":"GE Wynant","year":"1991","unstructured":"Wynant, G. E. et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate \n                           18, 229\u2013241 (1991).","journal-title":"Prostate"},{"key":"5481_CR20","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.7150\/thno.13348","volume":"5","author":"S Lutje","year":"2015","unstructured":"Lutje, S. et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics \n                           5, 1388\u20131401 (2015).","journal-title":"Theranostics"},{"key":"5481_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil, C. et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med \n                           57, 1941\u20131944 (2016).","journal-title":"J Nucl Med"},{"key":"5481_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/RLU.0000000000001654","volume":"42","author":"HD Zacho","year":"2017","unstructured":"Zacho, H. D., Nielsen, J. B., Dettmann, K., Haberkorn, U. & Petersen, L. J. Incidental detection of thyroid metastases from renal cell carcinoma using 68Ga-PSMA PET\/CT to assess prostate cancer recurrence. Clin Nucl Med \n                           42, 221\u2013222 (2017).","journal-title":"Clin Nucl Med"},{"key":"5481_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s13139-016-0408-y","volume":"50","author":"NA Damle","year":"2016","unstructured":"Damle, N. A. et al. Unusual uptake of prostate specific tracer 68Ga-PSMA-HBED-CC in a benign thyroid nodule. Nucl Med Mol Imaging \n                           50, 344\u2013347 (2016).","journal-title":"Nucl Med Mol Imaging"},{"key":"5481_CR24","doi-asserted-by":"publisher","unstructured":"Derlin, T., Kreipe, H. H., Schumacher, U. & Soudah, B. PSMA expression in tumor neovasculature endothelial cells of follicular thyroid adenoma as identified by molecular imaging using 68Ga-PSMA ligand PET\/CT. Clin Nucl Med. doi:10.1097\/RLU.0000000000001487 (2016).","DOI":"10.1097\/RLU.0000000000001487"},{"key":"5481_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/RLU.0000000000001084","volume":"41","author":"GL Kanthan","year":"2016","unstructured":"Kanthan, G. L., Drummond, J., Schembri, G. P., Izard, M. A. & Hsiao, E. Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET\/CT. Clin Nucl Med \n                           41, 331\u2013332 (2016).","journal-title":"Clin Nucl Med"},{"key":"5481_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2967\/jnmt.115.171660","volume":"44","author":"S Sager","year":"2016","unstructured":"Sager, S., Vatankulu, B., Uslu, L. & Sonmezoglu, K. Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET\/CT imaging. J Nucl Med Technol \n                           44, 199\u2013200 (2016).","journal-title":"J Nucl Med Technol"},{"key":"5481_CR27","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1097\/RLU.0000000000001148","volume":"41","author":"SK Taywade","year":"2016","unstructured":"Taywade, S. K., Damle, N. A. & Bal, C. PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer? Clin Nucl Med \n                           41, e263\u2013265, doi:10.1097\/RLU.0000000000001148 (2016).","journal-title":"Clin Nucl Med"},{"key":"5481_CR28","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00259-015-3065-y","volume":"42","author":"FA Verburg","year":"2015","unstructured":"Verburg, F. A., Krohn, T., Heinzel, A., Mottaghy, F. M. & Behrendt, F. F. First evidence of PSMA expression in differentiated thyroid cancer using 68Ga-PSMA-HBED-CC PET\/CT. Eur J Nucl Med Mol Imaging \n                           42, 1622\u20131623 (2015).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5481_CR29","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1089\/thy.2016.0100","volume":"26","author":"JJ Wiltshire","year":"2016","unstructured":"Wiltshire, J. J., Drake, T. M., Uttley, L. & Balasubramanian, S. P. Systematic review of trends in the incidence rates of thyroid cancer. Thyroid \n                           26, 1541\u20131552 (2016).","journal-title":"Thyroid"},{"key":"5481_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen, B. R. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid \n                           26, 1\u2013133 (2016).","journal-title":"Thyroid"},{"key":"5481_CR31","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res \n                           59, 3192\u20133198 (1999).","journal-title":"Cancer Res"},{"key":"5481_CR32","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","volume":"37","author":"E Demirci","year":"2016","unstructured":"Demirci, E. et al. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging. Nucl Med Commun \n                           37, 1169\u20131179 (2016).","journal-title":"Nucl Med Commun"},{"key":"5481_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/RLU.0000000000001454","volume":"42","author":"S Lutje","year":"2017","unstructured":"Lutje, S. et al. Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET\/CT. Clin Nucl Med \n                           42, 20\u201325 (2017).","journal-title":"Clin Nucl Med"},{"key":"5481_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.urolonc.2011.04.002","volume":"31","author":"A Chaux","year":"2013","unstructured":"Chaux, A. et al. Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: implications for novel intraoperative PSMA-based fluorescent imaging techniques. Urol Oncol \n                           31, 572\u2013575 (2013).","journal-title":"Urol Oncol"},{"key":"5481_CR35","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/modpathol.2008.143","volume":"21","author":"IO Gordon","year":"2008","unstructured":"Gordon, I. O. et al. Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol \n                           21, 1421\u20131427 (2008).","journal-title":"Mod Pathol"},{"key":"5481_CR36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2967\/jnumed.115.164442","volume":"57","author":"T Pyka","year":"2016","unstructured":"Pyka, T. et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med \n                           57, 367\u2013371 (2016).","journal-title":"J Nucl Med"},{"key":"5481_CR37","doi-asserted-by":"publisher","unstructured":"Kirchner, J. et al. Evaluation of practical interpretation hurdles in 68Ga-PSMA PET\/CT in 55 patients: physiological tracer distribution and incidental tracer uptake. Clin Nucl Med, doi:10.1097\/RLU.0000000000001672 (2017).","DOI":"10.1097\/RLU.0000000000001672"},{"key":"5481_CR38","doi-asserted-by":"publisher","unstructured":"Hofman, M. S. et al. First in-man study of 68Ga-THP-PSMA PET in patients with primary prostate cancer: initial results. Endocrine Abstracts OC31, doi:10.1530\/endoabs.47.OC31 (2016).","DOI":"10.1530\/endoabs.47.OC31"},{"key":"5481_CR39","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.clgc.2016.09.002","volume":"15","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian, J. J. et al. Correlation of PSMA-targeted 18F-DCFPyL PET\/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer. Clin Genitourin Cancer \n                           15, e65\u2013e68, doi:10.1016\/j.clgc.2016.09.002 (2017).","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 10","key":"5481_CR40","first-page":"S13","volume":"6","author":"SS Chang","year":"2004","unstructured":"Chang, S. S. Overview of prostate-specific membrane antigen. Rev Urol \n                           6(Suppl 10), S13\u201318 (2004).","journal-title":"Rev Urol"},{"key":"5481_CR41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ijc.2910620511","volume":"62","author":"JK Troyer","year":"1995","unstructured":"Troyer, J. K., Beckett, M. L. & Wright, G. L. Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer \n                           62, 552\u2013558 (1995).","journal-title":"Int J Cancer"},{"key":"5481_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.pathol.2016.04.002","volume":"48","author":"A Bychkov","year":"2016","unstructured":"Bychkov, A., Sampatanukul, P., Shuangshoti, S. & Keelawat, S. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma. Pathology \n                           48, 425\u2013433 (2016).","journal-title":"Pathology"},{"key":"5481_CR43","unstructured":"DeLellis, R. A., Lloyd, R. V., Heitz, P. U. & Eng, C. Pathology and genetics of tumours of endocrine organs 3rd edn (IARC Press, 2004)."},{"key":"5481_CR44","doi-asserted-by":"publisher","first-page":"R301","DOI":"10.1530\/ERC-15-0300","volume":"22","author":"F Vaisman","year":"2015","unstructured":"Vaisman, F., Carvalho, D. P. & Vaisman, M. A new appraisal of iodine refractory thyroid cancer. Endocr Relat Cancer \n                           22, R301\u2013310, doi:10.1530\/ERC-15-0300 (2015).","journal-title":"Endocr Relat Cancer"},{"key":"5481_CR45","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/jcp.56.8.638","volume":"56","author":"H Hattori","year":"2003","unstructured":"Hattori, H. Caution should be taken in using CD31 for distinguishing the vasculature of lymph nodes. J Clin Pathol \n                           56, 638\u2013639 (2003).","journal-title":"J Clin Pathol"},{"key":"5481_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/pros.22894","volume":"75","author":"Y Miyata","year":"2015","unstructured":"Miyata, Y. et al. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy. Prostate \n                           75, 84\u201391 (2015).","journal-title":"Prostate"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05481-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05481-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05481-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T01:30:24Z","timestamp":1671759024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05481-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["5481"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-05481-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,12]]},"assertion":[{"value":"30 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5202"}}